DelveInsight’s “Advanced Ovarian Cancer Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Advanced Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products, therapeutics assessment by product type, stage, route of administration, and molecule type, and highlights the inactive pipeline products in this space.
Discover Key Insights into the Advanced Ovarian Cancer Pipeline with DelveInsight’s In-Depth Report @ https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight
Key Takeaways from the Advanced Ovarian Cancer Pipeline Report
- On April 14, 2026- Pfizer conducted a Avelumab Continuation Sub-Studies to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.
- On April 13, 2026- Merck Sharp & Dohme LLC initiated a phase 3 study to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.
- On April 06, 2026- Tasly Pharmaceuticals Group Co. Ltd annouced a phase I/IIa study consisting of two parts, Phase I (dose escalation and PK bridging) and Phase IIa (dose expansion). Subjects in each cohort of Phase I will be administered 3 scheduled dose levels of STRO-002 as monotherapy by intravenous infusion until intolerable toxicity, radiographic disease progression, or subject withdrawal for other reasons. 5 dose arms are tentatively set based on the available safety, PK and efficacy data of STRO-002 for the Phase IIa (dose expansion).
- On March 05, 2026- Merck Sharp & Dohme LLC initiated a phase 3 study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.
- On March 02, 2026- AstraZeneca conducted a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of maintenance olaparib compared with placebo in BRCAwt participants with Stage III to IV high grade serous or endometroid ovarian cancer (including fallopian tube cancer or primary peritoneal cancer) who are in complete or partial response following treatment with standard first-line platinum-based chemotherapy.
- There are approximately 10+ key companies which are developing therapies for Advanced Ovarian Cancer, with around 12+ products under different phases of clinical development.
- Advanced Ovarian Cancer is the leading cause of death in women diagnosed with gynecological cancers. It is also the fifth most frequent cause of death in women, in general.
- Most of the cases are diagnosed at an advanced stage, which leads to poor outcomes of this disease. The existing screening tests have a low predictive value contributing further to this misery.
- Advanced Ovarian Cancer can present with a range of symptoms, including persistent abdominal pain, bloating, changes in bowel or urinary habits, and unexplained weight loss. Patients may experience fatigue, difficulty eating, back pain, or pain during sex.
- The pathophysiology of Advanced Ovarian Cancer involves the uncontrolled growth and spread of malignant ovarian cells. These cancer cells often invade surrounding tissues and organs, leading to the formation of secondary tumors.
- Measurement of CA-125 levels is usually done in adjunction with imaging. CA-125 is elevated in most of the epithelial ovarian cancers overall, but only half of the early stage epithelial ovarian cancers.
- The leading Advanced Ovarian Cancer Companies such as Allarity Therapeutics, AP Biosciences, Inc./Tasly Biopharmaceuticals Co., A2 Biotherapeutics Inc., Accent Therapeutics, Verismo Therapeutics, and others.
- Promising Advanced Ovarian Cancer Pipeline Therapies such as Stenoparib, B1962, A2B694, ATX-295, SynKIR-110, and others.
Stay ahead in the Advanced Ovarian Cancer Pipeline with DelveInsight’s Strategic Report @ https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight
Advanced Ovarian Cancer Pipeline Segmentation
- Advanced Ovarian Cancer Clinical Trial Phases (Late stage/Phase III, Mid-stage/Phase II, Early-stage/Phase I, Pre-clinical and Discovery stage, Discontinued & Inactive candidates)
- Advanced Ovarian Cancer Route of Administration (Oral, Intravenous, Subcutaneous, Parenteral, Topical)
- Advanced Ovarian Cancer Molecule Type (Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy)
- Advanced Ovarian Cancer Product Type (Mono, Combination, Mono/Combination)
Download the report to understand Advanced Ovarian Cancer Pipeline Development Activities @ https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight
Key Advanced Ovarian Cancer Pipeline Therapies
- Stenoparib: Allarity Therapeutics Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the Wnt signaling pathway. Aberrant Wnt/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking Wnt pathway activation, stenoparib’s unique therapeutic action shows potential as a promising therapeutic. Allarity has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. Some approved PARP inhibitors have recently been shown to be associated with less favorable survival outcomes than initially established. Allarity’s Phase II trial data for stenoparib to date shows that the drug has much less myelotoxicity than the FDA approved PARP inhibitors. Currently, the drug is in the Phase II stage of its development for the treatment of Advanced Ovarian Cancer. The companies which have their Advanced Ovarian Cancer drug candidates in the most advanced stage, i.e. Phase II includes Allarity Therapeutics.
- ATX-295: Accent Therapeutics ATX-295 is an investigational small-molecule therapy developed by Accent Therapeutics for the treatment of solid tumors. It is a selective inhibitor of KIF18A, a mitotic kinesin protein essential for cell division in cancers with chromosomal instability. By targeting this pathway, ATX-295 induces mitotic arrest and tumor cell death while sparing normal cells. The drug is currently in Phase I/II clinical development, with studies evaluating its safety, tolerability, and preliminary anti-tumor activity across multiple cancer types.
To know more about Advanced Ovarian Cancer treatment landscape, visit @ https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight
Advanced Ovarian Cancer Pipeline Companies
- Allarity Therapeutics
- AP Biosciences, Inc./Tasly Biopharmaceuticals Co.
- A2 Biotherapeutics Inc.
- Accent Therapeutics
- Verismo Therapeutics
- And others
Advanced Ovarian Cancer Pipeline Drugs
- Stenoparib
- B1962
- A2B694
- ATX-295
- SynKIR-110
- And others
Advanced Ovarian Cancer Disease Dynamics
The pathophysiology of Advanced Ovarian Cancer involves the uncontrolled growth and spread of malignant ovarian cells. These cancer cells often invade surrounding tissues and organs, leading to the formation of secondary tumors. As the cancer progresses, it can cause fluid accumulation (ascites), obstruct normal organ function, and spread to distant sites such as the lungs or abdomen, disrupting normal physiological processes. The tumor’s ability to resist treatment and recur further complicates disease management. The cancer cells can also secrete various growth factors that promote angiogenesis, enabling tumor growth and metastasis. For many years the optimal treatment for women with advanced ovarian cancer has been surgical cytoreduction followed by intravenous platinum and taxane chemotherapy on an every three-week schedule. Recent clinical trials suggest that new treatment paradigms with different routes, dosing schedules and addition of targeted biologic therapies are replacing this old standard.
Learn more about Advanced Ovarian Cancer Pipeline Drugs @ https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight
Scope of the Advanced Ovarian Cancer Pipeline Report
- Coverage- Global
- Advanced Ovarian Cancer Companies- Allarity Therapeutics, AP Biosciences, Inc./Tasly Biopharmaceuticals Co., A2 Biotherapeutics Inc., Accent Therapeutics, Verismo Therapeutics, and others
- Advanced Ovarian Cancer Pipeline Therapies- Stenoparib, B1962, A2B694, ATX-295, SynKIR-110, and others
- Advanced Ovarian Cancer Pipeline Analysis, Therapeutic Assessment, Clinical Trial Activities, Pipeline Development Activities
Table of Content
- Introduction
- Executive Summary
- Advanced ovarian cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Advanced ovarian cancer – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Advanced ovarian cancer Collaboration Deals
- Late Stage Products (Phase III)
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Stenoparib – Allarity Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- DS-6000a: Daiichi Sankyo Company
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Advanced ovarian cancer Key Companies
- Advanced ovarian cancer Key Products
- Advanced ovarian cancer- Unmet Needs
- Advanced ovarian cancer- Market Drivers and Barriers
- Advanced ovarian cancer- Future Perspectives and Conclusion
- Advanced ovarian cancer Analyst Views
- Advanced ovarian cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
